Crenezumab
- Generic Name
- Crenezumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1095207-05-8
- Unique Ingredient Identifier
- O8AS5277H0
- Background
Crenezumab has been used in trials studying the treatment of Alzheimer's Disease.
- Associated Conditions
- -
- Associated Therapies
- -
Tau Positron Emission Tomography (PET) Longitudinal Substudy Associated With: Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers in the Treatment of Autosomal-Dominant Alzheimer's Disease
- Conditions
- Interventions
- First Posted Date
- 2019-06-06
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 114
- Registration Number
- NCT03977584
- Locations
- 🇨🇴
Grupo Neurociencias de Antioquia, Medellin, Colombia
An Open-Label Crenezumab Study in Participants With Alzheimer's Disease
- First Posted Date
- 2018-04-09
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 149
- Registration Number
- NCT03491150
- Locations
- 🇺🇸
Anderson Clinical Research, Inc., Redlands, California, United States
🇺🇸University of California, Davis; Alzheimers Disease Center, Department of Neurology, Sacramento, California, United States
🇫🇷Hopital La Grave; Place Lange, Toulouse Cedec, France
A Study of Crenezumab Versus Placebo to Evaluate the Efficacy and Safety in Participants With Prodromal to Mild Alzheimer's Disease (AD)
- First Posted Date
- 2017-04-14
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 806
- Registration Number
- NCT03114657
- Locations
- 🇺🇸
Texas Neurology PA, Dallas, Texas, United States
🇮🇹Umberto I Policlinico di Roma-Università di Roma La Sapienza, Roma, Lazio, Italy
🇪🇸Hospital General Universitario de Elche; Servicio de NeurologÃa, Elche, Alicante, Spain
A Study Evaluating the Efficacy and Safety of Crenezumab Versus Placebo in Participants With Prodromal to Mild Alzheimer's Disease (AD).
- First Posted Date
- 2016-02-01
- Last Posted Date
- 2020-07-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 813
- Registration Number
- NCT02670083
- Locations
- 🇺🇸
Brain Matters Research, Inc., Delray Beach, Florida, United States
🇺🇸Quantum Laboratories, Deerfield Beach, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
A Study in Healthy Volunteers to Assess the Relative Bioavailability and Tolerability of Two Crenezumab Formulations Following Administration of a Single Subcutaneous Dose
- First Posted Date
- 2015-04-27
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 60
- Registration Number
- NCT02427243
A Study of Crenezumab Versus Placebo in Preclinical Presenilin1 (PSEN1) E280A Mutation Carriers to Evaluate Efficacy and Safety in the Treatment of Autosomal-Dominant Alzheimer's Disease (AD), Including a Placebo-Treated Non-Carrier Cohort
- First Posted Date
- 2013-12-02
- Last Posted Date
- 2024-07-30
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 252
- Registration Number
- NCT01998841
- Locations
- 🇨🇴
Grupo Neurociencias de Antioquia, Medellin, Colombia
🇨🇴Hospital San Juan de Dios, Yarumal, Colombia
🇨🇴ClÃnica de Marly, Bogota, Colombia
A Long-Term Safety Extension of Studies ABE4869g and ABE4955g in Participants With Mild to Moderate Alzheimer's Disease Treated With Crenezumab
- First Posted Date
- 2012-11-08
- Last Posted Date
- 2020-02-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT01723826
- Locations
- 🇨🇦
Toronto Memory Program (Neurology Research Inc.), Toronto, Ontario, Canada
🇺🇸University of California Los Angeles (UCLA), Los Angeles, California, United States
🇺🇸Margolin Brain Institute, Fresno, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.